Karolina Pytka

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1021760/publications.pdf Version: 2024-02-01



ΚΑΡΟΙΙΝΙΑ ΡΥΤΚΑ

#	Article	IF	CITATIONS
1	Serotonin receptors in depression and anxiety: Insights from animal studies. Life Sciences, 2018, 210, 106-124.	2.0	124
2	Essential elements in depression and anxiety. Part I. Pharmacological Reports, 2014, 66, 534-544.	1.5	122
3	Essential elements in depression and anxiety. Part II. Pharmacological Reports, 2015, 67, 187-194.	1.5	74
4	The role of serotonergic, adrenergic and dopaminergic receptors in antidepressant-like effect. Pharmacological Reports, 2016, 68, 263-274.	1.5	63
5	The role of glutamatergic, GABA-ergic, and cholinergic receptors in depression and antidepressant-like effect. Pharmacological Reports, 2016, 68, 443-450.	1.5	54
6	Synthesis and Evaluation of Antidepressantâ€like Activity of Some 4â€6ubstituted 1â€(2â€methoxyphenyl)Piperazine Derivatives. Chemical Biology and Drug Design, 2015, 85, 326-335.	1.5	50
7	Antidepressant- and Anxiolytic-Like Effects of New Dual 5-HT1A and 5-HT7 Antagonists in Animal Models. PLoS ONE, 2015, 10, e0142499.	1.1	39
8	Synthesis and preliminary evaluation of pharmacological properties of some piperazine derivatives of xanthone. Bioorganic and Medicinal Chemistry, 2013, 21, 514-522.	1.4	37
9	Synthesis and evaluation of pharmacological properties of some new xanthone derivatives with piperazine moiety. Bioorganic and Medicinal Chemistry Letters, 2013, 23, 4419-4423.	1.0	35
10	Antidepressant-like activity of a new piperazine derivative of xanthone in the forced swim test in mice: The involvement of serotonergic system. Pharmacological Reports, 2015, 67, 160-165.	1.5	32
11	A Comparison of the Anorectic Effect and Safety of the Alpha2-Adrenoceptor Ligands Guanfacine and Yohimbine in Rats with Diet-Induced Obesity. PLoS ONE, 2015, 10, e0141327.	1.1	28
12	Novel 3-(1,2,3,6-Tetrahydropyridin-4-yl)-1 <i>H</i> -indole-Based Multifunctional Ligands with Antipsychotic-Like, Mood-Modulating, and Procognitive Activity. Journal of Medicinal Chemistry, 2017, 60, 7483-7501.	2.9	25
13	H3 histamine receptor antagonist pitolisant reverses some subchronic disturbances induced by olanzapine in mice. Metabolic Brain Disease, 2016, 31, 1023-1029.	1.4	24
14	Revisiting the sigma-1 receptor as a biological target to treat affective and cognitive disorders. Neuroscience and Biobehavioral Reviews, 2022, 132, 1114-1136.	2.9	24
15	The antidepressant-like activity of 6-methoxy-2-[4-(2-methoxyphenyl)piperazin-1-yl]-9H-xanthen-9-one involves serotonergic 5-HT1A and 5-HT2A/C receptors activation. European Journal of Pharmacology, 2015, 764, 537-546.	1.7	23
16	The Calcium/Calmodulin-Dependent Kinases II and IV as Therapeutic Targets in Neurodegenerative and Neuropsychiatric Disorders. International Journal of Molecular Sciences, 2021, 22, 4307.	1.8	23
17	Novel Aryloxyethyl Derivatives of 1-(1-Benzoylpiperidin-4-yl)methanamine as the Extracellular Regulated Kinases 1/2 (ERK1/2) Phosphorylation-Preferring Serotonin 5-HT _{1A} Receptor-Biased Agonists with Robust Antidepressant-like Activity. Journal of Medicinal Chemistry, 2019. 62, 2750-2771	2.9	21
18	Single Administration of HBK-15—a Triple 5-HT1A, 5-HT7, and 5-HT3 Receptor Antagonist—Reverses Depressive-Like Behaviors in Mouse Model of Depression Induced by Corticosterone. Molecular Neurobiology, 2018, 55, 3931-3945.	1.9	20

Karolina Pytka

#	Article	IF	CITATIONS
19	The antidepressant- and anxiolytic-like activities of new xanthone derivative with piperazine moiety in behavioral tests in mice. Indian Journal of Pharmacology, 2016, 48, 286.	0.4	20
20	HBK-15 protects mice from stress-induced behavioral disturbances and changes in corticosterone, BDNF, and NGF levels. Behavioural Brain Research, 2017, 333, 54-66.	1.2	18
21	Biased agonism in drug discovery: Is there a future for biased 5-HT1A receptor agonists in the treatment of neuropsychiatric diseases?. , 2021, 227, 107872.		18
22	Cardiovascular activity of the chiral xanthone derivatives. Bioorganic and Medicinal Chemistry, 2015, 23, 6714-6724.	1.4	17
23	Chemically Homogenous Compounds with Antagonistic Properties at All α1-Adrenoceptor Subtypes but not β1-Adrenoceptor Attenuate Adrenaline-Induced Arrhythmia in Rats. Frontiers in Pharmacology, 2016, 7, 229.	1.6	17
24	HBK-7 — A new xanthone derivative and a 5-HT1A receptor antagonist with antidepressant-like properties. Pharmacology Biochemistry and Behavior, 2016, 146-147, 35-43.	1.3	17
25	Antidepressant-like activity of aroxyalkyl derivatives of 2-methoxyphenylpiperazine and evidence for the involvement of serotonin receptor subtypes in their mechanism of action. Pharmacology Biochemistry and Behavior, 2016, 141, 28-41.	1.3	17
26	The role of melatonin, neurokinin, neurotrophic tyrosine kinase and glucocorticoid receptors in antidepressant-like effect. Pharmacological Reports, 2017, 69, 546-554.	1.5	16
27	Metabolic and Cardiovascular Benefits and Risks of EMD386088—A 5-HT6 Receptor Partial Agonist and Dopamine Transporter Inhibitor. Frontiers in Neuroscience, 2017, 11, 50.	1.4	16
28	HBK-14 and HBK-15 with antidepressant-like and/or memory-enhancing properties increase serotonin levels in the hippocampus after chronic treatment in mice. Metabolic Brain Disease, 2017, 32, 547-556.	1.4	15
29	HBK-17, a 5-HT1A Receptor Ligand With Anxiolytic-Like Activity, Preferentially Activates ß-Arrestin Signaling. Frontiers in Pharmacology, 2018, 9, 1146.	1.6	15
30	Discovery of Novel pERK1/2- or β-Arrestin-Preferring 5-HT _{1A} Receptor-Biased Agonists: Diversified Therapeutic-like versus Side Effect Profile. Journal of Medicinal Chemistry, 2020, 63, 10946-10971.	2.9	15
31	HBK-14 and HBK-15, triple 5-HT 1A , 5-HT 7 and 5-HT 3 antagonists with potent antidepressant- and anxiolytic-like properties, increase seizure threshold in various seizure tests in mice. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 2017, 79, 378-385.	2.5	14
32	Antiarrhythmic, hypotensive and $\hat{l}\pm 1$ -adrenolytic properties of new 2-methoxyphenylpiperazine derivatives of xanthone. European Journal of Pharmacology, 2014, 735, 10-16.	1.7	11
33	The selective 5-HT1A receptor biased agonists, F15599 and F13714, show antidepressant-like properties after a single administration in the mouse model of unpredictable chronic mild stress. Psychopharmacology, 2021, 238, 2249-2260.	1.5	11
34	Evaluation of antidepressant-like and anxiolytic-like activity of purinedione-derivatives with affinity for adenosine A2A receptors in mice. Pharmacological Reports, 2016, 68, 1285-1292.	1.5	10
35	Design, synthesis and anticonvulsant-analgesic activity of new N-[(phenoxy)alkyl]- and N-[(phenoxy)ethoxyethyl]aminoalkanols. MedChemComm, 2017, 8, 220-238.	3.5	10
36	Antiarrhythmic activity of new 2-methoxyphenylpiperazine xanthone derivatives after ischemia/reperfusion in rats. Pharmacological Reports, 2015, 67, 1163-1167.	1.5	9

Karolina Pytka

#	Article	IF	CITATIONS
37	Biofunctional studies of new 2-methoxyphenylpiperazine xanthone derivatives with α1-adrenolytic properties. Pharmacological Reports, 2015, 67, 267-274.	1.5	8
38	HBK-14 and HBK-15 Do Not Influence Blood Pressure, Lipid Profile, Glucose Level, or Liver Enzymes Activity after Chronic Treatment in Rats. PLoS ONE, 2016, 11, e0165495.	1.1	8
39	Synthesis and activity of di- or trisubstituted N -(phenoxyalkyl)- or N -{2-[2-(phenoxy)ethoxy]ethyl}piperazine derivatives on the central nervous system. Bioorganic and Medicinal Chemistry Letters, 2018, 28, 2039-2049.	1.0	7
40	Design, synthesis and evaluation of activity and pharmacokinetic profile of new derivatives of xanthone and piperazine in the central nervous system. Bioorganic and Medicinal Chemistry Letters, 2019, 29, 126679.	1.0	7
41	Antihistaminic activity of carane derivatives in isolated guinea pig ileum. Pharmacological Reports, 2009, 61, 1211-1215.	1.5	5
42	Pitolisant protects mice chronically treated with corticosterone from some behavioral but not metabolic changes in corticosterone-induced depression model. Pharmacology Biochemistry and Behavior, 2020, 196, 172974.	1.3	5
43	Synthesis of N â€(phenoxyalkyl)â€, N â€{2â€{2â€(phenoxy)ethoxy]ethyl}―or N â€(phenoxyacetyl)piperazine Derivatives and Their Activity Within the Central Nervous System. ChemistrySelect, 2019, 4, 9381-9391.	0.7	4
44	Multifunctional 6-fluoro-3-[3-(pyrrolidin-1-yl)propyl]-1,2-benzoxazoles targeting behavioral and psychological symptoms of dementia (BPSD). European Journal of Medicinal Chemistry, 2020, 191, 112149.	2.6	4
45	Mitogenâ€activated protein kinase phosphataseâ€2 deletion modifies ventral tegmental area function and connectivity and alters reward processing. European Journal of Neuroscience, 2020, 52, 2838-2852.	1.2	4
46	Synthesis and Evaluation of the Antidepressant-like Properties of HBK-10, a Novel 2-Methoxyphenylpiperazine Derivative Targeting the 5-HT1A and D2 Receptors. Pharmaceuticals, 2021, 14, 744.	1.7	4
47	The antidepressant-like activity of chiral xanthone derivatives may be mediated by 5-HT1A receptor and β-arrestin signalling. Journal of Psychopharmacology, 2020, 34, 1431-1442.	2.0	2
48	The Antiarrhythmic Activity of Novel Pyrrolidin-2-one Derivative S-75 in Adrenaline-Induced Arrhythmia. Pharmaceuticals, 2021, 14, 1065.	1.7	1
49	PRELIMINARY EVALUATION OF CENTRAL NERVOUS SYSTEM ACTIVITY OF (E)-N-2-METHYL-3-PHENYLPROP-2-ENYL ((E)-N- α-METHYLCINNAMYL) DERIVATIVES OF SELECTED AMINOALKANOLS. Acta Poloniae Pharmaceutica, 2016, 73, 345-57.	0.3	1
50	Protease-activated receptor 2 activation induces behavioural changes associated with depression-like behaviour through microglial-independent modulation of inflammatory cytokines. Psychopharmacology, 2022, 239, 229-242.	1.5	1
51	Scopolamine hydrobromide is indeed a proper memory impairments inductor in mice. European Neuropsychopharmacology, 2017, 27, S668-S669.	0.3	0